TruSight Oncology 500

Assay targeting multiple variant types, including microsatellite instability (MSI) and tumor mutational burden (TMB). Read More...

This product is only available in select locations. Please select the location where you would like this product to be shipped to see availability.

Select Product(s)
What do I need?
Manual Prep

TruSight Oncology 500 HRD Kit (24 samples)

20076480

TruSight Oncology 500 DNA Kit (48 samples)

20028213

Price
 
 

TruSight Oncology 500 DNA Kit, For Use with NextSeq (48 samples)

20028214

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle, (16 indexes, 24 samples)

20028215

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle, for use with NextSeq (16 indexes, 24 samples)

20028216

Price
 
 

TruSight Oncology 500 DNA Kit plus Velsera interpretation report (16 indexes, 48 Samples)

20032624

Price
 
 

TruSight Oncology 500 DNA Kit for Use with NextSeq plus Velsera interpretation report (16 indexes, 48 Samples)

20032625

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle plus Velsera interpretation report (16 indexes, 24 Samples) 

20032626

Price
 
 

TruSight Oncology 500 DNA/RNA Kit for Use with NextSeq plus Velsera interpretation report (16 indexes, 24 Samples) 

20032627

Price
 
 

Automation

TruSight Oncology 500 DNA Automation Kit (16 indexes, 64 Samples)

20045504

Price
 
 

TruSight Oncology 500 DNA Automation Kit, For Use with NextSeq (16 indexes, 64 Samples)

20045505

Price
 
 

TruSight Oncology 500 DNA Automation Kit plus Pierian interpretation report (16 indexes, 64 samples)

20045506

Price
 
 

TruSight Oncology 500 DNA Automation Kit plus Pierian interpretation report, for Use with NextSeq (16 indexes, 64 samples)

20045507

Price
 
 

TruSight Oncology 500 DNA/RNA Automation Kit (16 indexes, 32 Samples)

20045508

Price
 
 

TruSight Oncology 500 DNA/RNA Automation Kit plus Pierian interpretation report (16 indexes, 32 Samples)

20045509

Price
 
 

TruSight Oncology 500 DNA/RNA Automation Kit, For Use with NextSeq (16 indexes, 32 Samples)

20045990

Price
 
 

TruSight Oncology 500 DNA/RNA Automation Kit plus Pierian interpretation report, For Use with NextSeq (16 indexes, 32 Samples)

20045991

Price
 
 

Services

TruSight Oncology 500 Training (DNA, optional HRD) - Customer Site

20031667

Price
 
 

TruSight Oncology 500 Training (DNA and RNA, optional HRD) - Customer Site

20031668

Price
 
 

Software and Informatics Options

Illumina DRAGEN Server v3

20040619

Illumina DRAGEN Server v4

20051343

Price
 
 

DRAGEN TruSight Oncology 500 HRD Analysis Software, On-Premise

20073738

ICA Basic Annual Subscription

20044874

ICA Professional Annual Subscription

20044876

ICA Enterprise Annual Subscription

20038994

ICA Enterprise Service and Compliance Add-on (applies to Basic only)

20066830

Illumina Analytics - 1 iCredit

20042038

Price
 
 

Illumina Analytics  Starter Pack - 1,000 iCredits

20042039

Price
 
 

Illumina Analytics  - 5,000 iCredits

20042040

Price
 
 

Illumina Analytics  - 50,000 iCredits

20042041

Price
 
 

Illumina Analytics - 100,000 iCredits

20042042

Price
 
 

Illumina Connected Insights-Annual Subscription

20090137

Illumina Connected Insights‒Oncology Genome Equivalent Sample-VCF

20090138

Illumina Connected Insights‒Training and Onboarding

20092376

Informatics Professional Services

20071787

Product Highlights

TruSight Oncology 500 is a next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples. It supports identification of all relevant DNA and RNA variants implicated in various solid tumor types.

In addition, it accurately measures key current immuno-oncology biomarkers: microsatellite instability (MSI) and tumor mutational burden (TMB).

TruSight Oncology 500 HRD** is an optional add-on kit to TruSight Oncology 500 and enables detection of homologous recombination deficiency (HRD) through assessment of a genomic instability score (GIS). This represents an exciting new advancement to the TruSight Oncology portfolio.

**Not available in Japan.

Consolidate Multiple Biomarker Assays into One

  • Pan-cancer biomarker content aligned with key guidelines and clinical trials
  • 523 genes for assessment of all DNA and RNA variant types, plus microsatellite instability (MSI), tumor mutational burden (TMB) and homologous recombination deficiency (HRD)
  • Optional add-on HRD enrichment kit to assess loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large scale state transitions (LST) in one genomic instability (GIS) score, powered by Myriad Genetics.
  • Increase chances of finding a positive biomarker by moving from individual biomarker assays to a single comprehensive NGS assay

Streamlined Sample-to-Results Workflow

  • Go from initial sample to results in 4-5 days
  • Rapid variant calling algorithm powered by DRAGEN pipelines, available locally on DRAGEN server
  • Secure, scalable, cloud-based variant calling is available with DRAGEN pipelines on Illumina Connected Analytics (ICA) featuring auto-launch capability.
  • Automation kits and methods available for reduced hands-on time and increased scalability. (Not available for TruSight Oncology 500 HRD.)
  • Multiple verified tertiary analysis options available, including Illumina Connected Insights and Velsera Clinical Genomics Workspace

Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.

Achieve Highly Confident Results

  • Hybrid-capture chemistry combined with sophisticated bioinformatics, leading to high analytical specificity and sensitivity
  • Inclusive of unique molecular indexes (UMIs) for high sensitivity in variant detection
  • Based on proven Illumina SBS sequencing technology

Enable In-House Comprehensive Genomic Profiling

  • Keep samples and data in house, for more control and ability to build a database
  • A future-proof assay with emerging biomarkers already included

Fast, Automation-friendly Workflow

Prepare libraries for Illumina sequencing in less than a day. Illumina Qualified Methods are available on a range of automation platforms through our partners.

Learn more about the TruSight Oncology Product Family

view video about TruSight Oncology 500 HRD at Oncopole Toulouse (France) ft. Dr. Guillaume Bataillon

Play Video

TruSight Oncology 500 Portfolio

All three TruSight Oncology 500 assays are designed to identify key biomarkers in guidelines and clinical trials.

TruSight Oncology 500 Assay

Assess relevant biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.

TruSight Oncology 500 High-Throughput Assay

Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.

TruSight Oncology 500 ctDNA Assay

Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.

Interested in learning more about the TSO 500 portfolio of products? Download the overview brochure.

Purchasing the TruSight Oncology 500 assay for the first time?

Complete the form to receive information about the first-time TruSight Oncology 500 purchase program.

Frequently Purchased Together

Specifications

Product Comparison

TruSight Oncology 500 TruSight Oncology 500 High-Throughput TruSight Oncology 500 ctDNA v2
Cancer Type Pan-Cancer Pan-Cancer Pan-Cancer, Solid Tumor
Hands-On Time Manual: ~10.5 hrs
Automated: ~2.5 hrs (TruSight Oncology 500 only), Manual: ~10.5 hrs
Automated: ~2.5 hrs (TruSight Oncology 500 only)
Manual: ~10.5 hrs
Automated: ~2.5 hrs
~2.5 hours for library prep and enrichment
Input Quantity 40 ng DNA, 40 ng RNA 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue) 20 ng cfDNA (4 ml of plasma)
Method Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing Target Enrichment, Targeted DNA Sequencing
Nucleic Acid Type RNA, DNA RNA, DNA DNA
Specialized Sample Types FFPE Tissue FFPE Tissue Blood, Circulating Tumor DNA
Species Category Human Human Human
System Compatibility NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode NovaSeq 6000, NovaSeq 6000Dx in Research Mode NovaSeq 6000
Technology Sequencing Sequencing Sequencing
Variant Class Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants Copy Number Variants (CNVs), Insertions-Deletions (indels), Single Nucleotide Variants (SNVs)
Variant Class Details For TruSight Oncology 500 HRD, genomic instability score, and the following beta features - tumor fraction, tumor ploidy, absolute copy number, and gene-level loss of heterozygosity - are available. Beta features have not been verified by Illumina. See the v2.5+ customer release notes for more details. For TruSight Oncology 500 HRD, genomic instability score, and the following beta features - tumor fraction, tumor ploidy, absolute copy number, and gene-level loss of heterozygosity - are available. Beta features have not been verified by Illumina. See the v2.5+ customer release notes for more details.

*Based on Velsera clinical knowledgebase, as of February 2023.
NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.

 

Analytical Evaluation & Verification Service

The TruSight Oncology 500 Analytical Evaluation Service* is a set of tools intended to guide you in aligning with the latest CAP, AMP, and European standards. We provide recommendations to help you evaluate analytical performance characteristics and integrate products into your workflows.

Learn More
Analytical Evaluation & Verification Service

* This service is available in select countries and regions.

Method-Specific Workflow Example

 

Supporting Data and Figures

 
Pan-cancer: BRAF, NTRK1, NTRK2, NTRK3, RET, MSI, TMB
Genes with biomarkers of significance* Genes with biomarkers of potential significance
breast cancer
Breast
BRCA1 BRCA2 ERBB2 ESR1 PALB2 PIK3CA         180
colorectal cancer
Colorectal
ERBB2 KRAS NRAS               166
bone cancer
Bone
EGFR ERG ETV1 ETV4 EWSR1 FEV FLI1 FUS H3F3A HEY1 140
IDH1 MDM2 NCOA2 SMARCB1            
lung cancer
Lung
ALK EGFR ERBB2 KRAS MET NUTM1 ROS1       223
melanoma cancer
Melanoma
KIT NRAS ROS1               172
ovarian cancer
Ovarian
BRCA1 BRCA2 FOXL2               149
cns cancer
CNS
APC ATRX CDKN2A CDKN2B EGFR H3F3A HIST1H3B HIST1H3C IDH1 IDH2 140
MYCN PTCH1 RELA TERT TP53          
prostate cancer
Prostate
AR ATM BARD1 BRCA1 BRCA2 BRIP1 CDK12 CHEK1 CHEK2 FANCL 151
FGFR2 FGFR3 PALB2 RAD51B RAD51C RAD51D RAD54L      
thyroid cancer
Thyroid
HRAS KRAS NRAS RET TERT           165
uterine cancer
Uterine & cervical
BRCA2 EPC1 ERBB2 ESR1 FOXO1 GREB1 JAZF1 NCOA2 NCOA3 NUTM2A 138
NUTM2B PAX3 PAX7 PHF1 POLE SMARCA4 SUZ12 TP53 YWHAE  
other solid cancer tumors
Other Solid Tumors
ALK APC ARID1A ASPSCR1 ATF1 ATIC BAP1 BCOR BRCA1 BRCA2 152
CAMTA1 CARS CCNB2 CDK4 CDKN2A CIC CITED2 CLTC COL1A1 COL6A3
CREB1 CREB3L1 CREB3L2 CSF1 CTNNB1 DDIT3 DDX3X DNAJB1 DUX4 EED
EGFR ERBB2 ERG ETV1 ETV4 ETV6 EWSR1 FEV FGFR2 FGFR3
FLI1 FOXL2 FOXO1 FOXO4 FUS GLI1 HEY1 HGF HMGA2 IDH1
KRAS LEUTX MAML3 MDM2 MYB MYOD1 NAB2 NCOA2 NF1 NFATC2
NFIB NR4A3 NRAS NUTMI NUTM2A NUTM2B PALB2 PATZ1 PAX3 PAX7
PDGFB PDGFRA PRKACA PRKD1 RANBP2 ROS1 SDHA SDHB SDHC SDHD
SMARCB1 SS18 SSX1 SSX2 SSX4 STAT6 SUZ12 TAF15 TCF12 TERT
TFE3 TFEB TFG TP53 TPM3 TPM4 TRAF7 TSPAN31 VGLL2 WT1
WWTR1 YAP1 YWHAE ZC3H7B            

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on this page.

* The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.

Related Products